Table 1

Baseline demographic, clinical and radiographic characteristics

AssessmentN=184
mean (SD) or n (%)
Age (years)43 (12)
Male gender (%)129 (70%)
HLA-B27 positive (%)149 (83%)
Symptoms duration (years)20 (12)
Disease duration (years)11 (9)
ASDAS-CRP2.6 (1.0)
BASDAI (0–10)3.4 (2.0)
CRP (mg/L)17.4 (23.3)
Elevated CRP (%)*85 (48%)
ESR (mm/h)14.0 (15.0)
Patient's global assessment of disease activity (0–10)3.7 (2.7)
Spinal pain (0–10)3.5 (2.3)
mSASSS (0–72)10.8 (15.2)
mSASSS >0 (%)140 (81%)
NSAIDs (%)125 (68%)
Tumour necrosis factor α inhibitors (%)0 (0%)
  • *The cut-off was 10 mg/L for the Dutch patients and 5 mg/L for the Belgian and French patients.

  • ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score (C-reactive protein); BASDAI, Bath Ankylosing Spondylitis Disease Activity Score; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs.